Stemcyte, Inc. | MedPath

Spinal Cord Injury Treatment Market Poised for Growth with Emerging Therapies

4 months ago

• The spinal cord injury (SCI) market is projected to grow significantly, driven by increasing prevalence and advancements in treatment options. • Emerging therapies like KP-100IT, Neuro-Cells, and MT-3921 are expected to transform the SCI treatment landscape, offering new standards of care. • Clinical trials are underway for several promising SCI treatments, including NervGen Pharma's NVG-291 and Mitsubishi Tanabe Pharma's MT-3921. • The SCI market in the 7MM is estimated to increase from USD 345 million in 2023 to a CAGR of 15.4% by 2034, according to DelveInsight.